

# Contents

Preface.....	vii
<i>Vassil St. Georgiev</i>	

Acknowledgments.....	ix
----------------------	----

Contributors .....	xv
--------------------	----

## PART I INTRODUCTION

National Institute of Allergy and Infectious Diseases (NIAID): <i>An Overview</i> .....	3
<i>Karl A. Western</i>	

## PART II MICROBIOLOGY AND INFECTIOUS DISEASES

### Section 1 Emerging and Re-Emerging Infections

1 Biotools for Determining the Genetics of Susceptibility to Infectious Diseases and Expediting Research Translation into Effective Countermeasures .....	13
<i>Malak Kotb, Robert W. Williams, Nourtan Fathey, Mohamed Nooh, Sarah Rowe, Rita Kansal, and Ramy Aziz</i>	
2 Spore Surface Components and Protective Immunity to <i>Bacillus anthracis</i> .....	19
<i>Patricia Sylvestre, Ian Justin Glomski, Evelyne Couture-Tosi, Pierre Louis Goossens, and Michèle Mock</i>	
3 New Candidate Anthrax Pathogenic Factors .....	25
<i>Serguei G. Popov</i>	
4 <i>Ehrlichiae</i> and <i>Ehrlichioses: Pathogenesis and Vector Biology</i> .....	37
<i>H. L. Stevenson, N. Ismail, and D. H. Walker</i>	
5 Multiple Locus Variable Number Tandem Repeat (VNTR) Analysis (MLVA) of <i>Brucella</i> spp. Identifies Species-Specific Markers and Insights into Phylogenetic Relationships .....	47
<i>Lynn Y. Huynh, Matthew N. Van Ert, Ted Hadfield, William S. Probert, Bryan H. Bellaire, Michael Dobson, Robert J. Burgess, Robbin S. Weyant, Tanja Popovic, Shaylan Zanecki, David M. Wagner, and Paul Keim</i>	
6 Expression of the MtrC-MtrD-MtrE Efflux Pump in <i>Neisseria gonorrhoeae</i> and Bacterial Survival in the Presence of Antimicrobials.....	55
<i>William M. Shafer, Jason P. Folster, Douglas E. M. Warner, Paul J. T. Johnson, Jacqueline T. Balthazar, Nazia Kamal, and Ann E. Jerse</i>	

**Section 2 Tuberculosis**

- 7 What can Mycobacteriophages Tell Us About *Mycobacterium tuberculosis*? ..... 67  
*Graham F. Hatfull*
- 8 Clinical *Mycobacterium tuberculosis* Strains Differ in their Intracellular Growth in Human Macrophages ..... 77  
*Sue A. Theus, M. Donald Cave, and Kathleen D. Eisenach*
- 9 Mechanisms of Latent Tuberculosis: *Dormancy and Resuscitation of Mycobacterium tuberculosis* ..... 83  
*Galina Mukamolova, Elena Salina, and Arseny Kaprelyants*
- 10 Separating Latent and Acute Disease in the Diagnosis of Tuberculosis ..... 91  
*T. Mark Doherty*
- 11 Mutant Selection Window Hypothesis: *A Framework for Anti-mutant Dosing of Antimicrobial Agents* ..... 101  
*Karl Drlica and Xilin Zhao*

**Section 3 Avian Influenza**

- 12 The NIAID Influenza Genome Sequencing Project ..... 109  
*Lone Simonsen, Gayle Bernabe, Karen Lacourciere, Robert J. Taylor, and Maria Y. Giovanni*
- 13 Lessons from the 1918 Spanish Flu Epidemic in Iceland ..... 115  
*Magnús Gottfredsson*
- 14 Control of Notifiable Avian Influenza Infections in Poultry ..... 123  
*Ilaria Capua and Stefano Marangon*
- 15 Understanding the Complex Pathobiology of High Pathogenicity Avian Influenza Viruses in Birds ..... 131  
*David E. Swayne*

**Section 4 Prophylactics and Therapeutics for Infectious Diseases**

- 16 Development of Prophylactics and Therapeutics Against the Smallpox and Monkeypox Biothreat Agents ..... 145  
*Mark Buller, Lauren Handley, and Scott Parker*
- 17 The Hierarchic Informational Technology for QSAR Investigations: *Molecular Design of Antiviral Compounds* ..... 163  
*V. E. Kuz'min, A. G. Artemenko, E. N. Muratov, L. N. Ognichenko, A. I. Hromov, A. V. Liahovskij, and P. G. Polischuk*
- 18 Antivirals for Influenza: *Novel Agents and Approaches* ..... 179  
*William A Fischer, II and Frederick Hayden*
- 19 Anti-Infectious Actions of the Proteolysis Inhibitor  $\epsilon$ -Aminocaproic Acid ( $\epsilon$ -ACA) ..... 193  
*V. P. Lozitsky*
- 20 A New Highly Potent Antienteroviral Compound ..... 199  
*Lubomira Nikolaeva-Glomb, Stefan Philipov, and Angel S. Galabov*

**Section 5 Russian Perspectives in Emerging and Re-Emerging and Infections Research**

- 21 Reduction and Possible Mechanisms of Evolution of the Bacterial Genomes ..... 205  
*George B. Smirnov*
- 22 Interaction of *Yersinia pestis* Virulence Factors with IL-1R/TLR Recognition System ..... 215  
*Vyacheslav M. Abramov, Valentin S. Khlebnikov, Anatoly M. Vasiliev, Igor V. Kosarev, Raisa N. Vasilenko, Nataly L. Kulikova, Vladimir L. Motin, George B. Smirnov, Valentin I. Evstigneev, Nicolay N. Karkischenko, Vladimir N. Uversky, and Robert R. Brubaker*

Contents	xiii
----------	------

- |  |     |
|--|-----|
| 23 IS481-Induced Variability of <i>Bordetella pertussis</i> . . . . .  | 227 |
| <i>Ludmila N. Sinyashina, Alisa Yu. Medkova, Evgeniy G. Semin, Alexander V. Chestkov, Yuriy D. Tsygankov, and Gennagiy I. Karataev</i> |     |
| 24 Microarray Immunophorescence Technology for the Detection of Infectious Pathogens . . . . .   | 233 |
| <i>Nikolay S. Osin and Vera G. Pomelova</i>  |     |
| 25 Development of Immunodiagnostic Kits and Vaccines for Bacterial Infections . . . . .  | 241 |
| <i>Valentina A. Feodorova and Onega V. Ulianova</i>  |     |

## **Section 6 Perspectives in Emerging and Re-Emerging Infections—Research in Central Asia and Caucasus**

- |   |     |
|---|-----|
| 26 Research in Emerging and Re-Emerging Diseases in Central Asia and the Caucasus:<br><i>Contributions by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health</i> . . . . . | 251 |
| <i>Katherine T. Herz</i>  |     |
| 27 Disease Surveillance in Georgia: <i>Benefits of International Cooperation</i> . . . . .  | 253 |
| <i>Lela Bakanidze, Paata Imnadze, Shota Tsanava, and Nikoloz Tservadze</i>  |     |
| 28 Epidemiology (Including Molecular Epidemiology) of HIV, Hepatitis B and C in Georgia:<br><i>Experience From U.S.–Georgian Collaboration</i> . . . . .  | 257 |
| <i>Tengiz Tservadze</i>   |     |
| 29 The National Tuberculosis Program in the Country of Georgia: <i>An Overview</i> . . . . .  | 263 |
| <i>Archil Salakaia, Veriko Mirtskhulava, Shalva Gamtslidze, Marina Janjgava, Rusudan Aspindzelashvili, and Ucha Nanava</i>  |     |

## **PART III HUMAN IMMUNODEFICIENCY VIRUS AND AIDS**

- |  |     |
|--|-----|
| 30 Virus Receptor Wars: <i>Entry Molecules Used for and Against Viruses Associated with AIDS</i> . . . . . | 271 |
| <i>Edward A. Berger</i>  |     |
| 31 HIV Latency and Reactivation: <i>The Early Years</i> . . . . .  | 279 |
| <i>Guido Poli</i>  |     |
| 32 HIV-1 Sequence Diversity as a Window Into HIV-1 Biology . . . . .                                       | 289 |
| <i>Milloni Patel, Gretja Schnell, and Ronald Swanson</i>   |     |
| 33 Human Monoclonal Antibodies Against HIV and Emerging Viruses . . . . .                                  | 299 |
| <i>Dimitar S. Dimitrov</i>   |     |
| 34 Biological Basis and Clinical Significance of HIV Resistance to Antiviral Drugs . . . . .               | 309 |
| <i>Mark A. Wainberg and Susan Schader</i>  |     |
| 35 NIAID HIV/AIDS Prevention Research . . . . .  | 319 |
| <i>David N. Burns and Roberta Black</i>  |     |
| 36 Epidemiological Surveillance of HIV and AIDS in Lithuania . . . . .                                     | 327 |
| <i>Saulius Caplinskas</i>  |     |

## **PART IV IMMUNOLOGY AND VACCINES**

### **Section 1 Immunomodulation**

- |   |     |
|---|-----|
| 37 TACI, Isotype Switching, CVID, and IgAD . . . . .  | 343 |
| <i>Emanuela Castigli and Raif S. Geha</i>   |     |
| 38 A Tapestry of Immunotherapeutic Fusion Proteins: <i>From Signal Conversion to Auto-stimulation</i> . . . . . | 349 |
| <i>Mark L. Tykocinski, Jui-Han Huang, Matthew C. Weber, and Michal Dranitzki-Elhalel</i>                        |     |

- 39 A Role for Complement System in Mobilization and Homing of Hematopoietic Stem/Progenitor Cells ..... 357  
*M. Z. Ratajczak, R. Reca, M. Wysoczynski, M. Kucia, and J. Ratajczak*
- 40 Post-translational Processing of Human Interferon- $\gamma$  Produced in *Escherichia coli* and Approaches for Its Prevention ..... 365  
*Maya Boyanova, Roumyana Mironova, Toshimitsu Niwa, and Ivan G. Ivanov*

## Section 2 Autoimmunity

- 41 B-cell dysfunctions in Autoimmune Diseases ..... 377  
*Moncef Zouali*
- 42 A Model System for Studying Mechanisms of B-cell Transformation in Systemic Autoimmunity ..... 385  
*Wendy F. Davidson, Partha Mukhopadhyay, Mark S. Williams, Zohreh Naghashfar, Jeff X. Zhou, and Herbert C. Morse, III*
- 43 Breach and Restoration of B-Cell Tolerance in Human Systemic Lupus Erythematosus (SLE) ..... 397  
*Iñaki Sanz, R. John Looney, and J. H. Anolik*

## Section 3 Infection and Immunity

- 44 Dendritic Cells: *Biological and Pathological Aspects* ..... 409  
*Jacques Banchereau, John Connolly, Tiziana Di Puccio, Carson Harrod, Eynav Klechevsky, A. Karolina Palucka, Virginia Pascual, and Hideki Ueno*
- 45 Immunomic and Bioinformatics Analysis of Host Immunity in the Vaccinia Virus and Influenza A Systems ..... 429  
*Magdalini Moutaftsi, Bjoern Peters, Valerie Pasquetto, Carla Oseroff, John Sidney, Huynh Hoa-Bui, Howard Grey, and Alessandro Sette*
- 46 Immunoreactions to Hantaviruses ..... 435  
*Alemka Markotić and Connie Schmaljohn*
- 47 Innate Immunity to Mouse Cytomegalovirus ..... 445  
*Djurdjica Cekinović, Irena Slavuljica, Tihana Lenac, Astrid Krmpotić, Bojan Polić, and Stipan Jonjić*

## Section 4 Vaccines

- 48 Research and Development of Chimeric Flavivirus Vaccines ..... 459  
*Simon Delagrave and Farshad Guirakhoo*
- 49 Correlates of Immunity Elicited by Live *Yersinia pestis* Vaccine ..... 473  
*Vivian L. Braciale, Michael Nash, Namita Sinha, Irina V. Zudina, and Vladimir L. Motin*

## PART V BUILDING A SUSTAINABLE PERSONAL RESEARCH PORTFOLIO

- 50 Strategies for a Competitive Research Career ..... 483  
*Hortencia Hornbeck and Peter R. Jackson*
- 51 Selecting the Appropriate Funding Mechanism ..... 487  
*Priti Mehrotra, Hortencia Hornbeck, Peter R. Jackson, and Eugene Baizman*
- 52 Preparing and Submitting a Competitive Grant Application ..... 497  
*Peter R. Jackson and Hortencia Hornbeck*
- 53 Identifying Research Resources and Funding Opportunities ..... 507  
*Eugene Baizman, Hortencia Hornbeck, Peter R. Jackson, and Priti Mehrotra*
- Index ..... 519